SCAI Statement on Thyroid Monitoring in Young Children Receiving Iodinated Contrast Media
SCAI believes that the current data is insufficient to warrant the course of action described within the recent Food and Drug Administration Drug Safety Communication and that further studies are needed to define at-risk groups accurately, clarify the risks of ICM exposure, and provide rational monitoring and treatment guidelines.
Dec 21st, 2021
Article
President's Message—December 2021
Important changes to SCAI's relationship to CCI and subscriptions
Dec 8th, 2021
Article
SCAI Statement on Medicare Cuts
SCAI released the following statement in response to approval of the Further Extending Government Funding Act
Nov 29th, 2021
Article
Nov 19th, 2021
Article
Nov 16th, 2021
Article
Nov 5th, 2021
Article
SCAI Previews an Expert Consensus Update to SCAI SHOCK Stage Classification
The Society for Cardiovascular Angiography and Interventions (SCAI) has previewed a two-year update to the SCAI SHOCK classification that includes modific...